ALK, ROS1, NTRK, FGFR and RET fusions now define an important subset of non-small cell lung cancers (NSCLC) and other malignancies with FDA-approved targeted inhibitors (1–9). The gene discussed is RET; the disease is non-small cell lung carcinoma.